Traders should monitor the shareholder vote on July 8 and regulatory HSR/German clearance. The $3.16 cash price sets an effective floor near that level. CVR upside to $100M aggregate is real but contingent on achieving aggressive 2027 bempedoic acid sales ($300M+) or enbumyst sales ($160M+). If the deal closes, delisting will occur shortly after.
Price Chart
Executive Summary
The filing is a definitive merger proxy (DEFM14A) for Esperion Therapeutics' acquisition by ArchiMed for $3.16/share plus one CVR per share. The board unanimously recommends a FOR vote. The deal requires majority approval of outstanding shares, with the special meeting on July 8, 2026. Total transaction costs are ~$1.08 billion, funded by $706.1M equity commitments and up to $550M debt. CVRs offer up to $100M in total contingent payments tied to sales milestones.
Key Financial Metrics
Key Facts
- Merger consideration: $3.16/share cash + 1 CVR per share
- Total funding ~$1.08B: $706.1M equity from ArchiMed funds + up to $550M debt commitment from BPCR/ BioPharma Credit
- Special meeting July 8, 2026; required vote is majority of outstanding shares (257.7M shares outstanding)
- CVRs: up to $40M aggregate if U.S. bempedoic acid net sales exceed $300M in CY 2027 (max $350M); up to $60M if enbumyst U.S. net sales exceed $160M in any single CY through 2030
- Board and financial advisor Centerview Partners opined that consideration is fair from a financial point of view
- Company termination fee: $34.2M; Parent termination fee: $68.3M
- Expected close: Q3 2026; HSR and German merger control filings submitted May 15, 2026
- No dissenting directors; board recommendation was unanimous
Financial Impact
Total transaction size ~$1.08 billion in cash for equity and debt paydown/fees; $3.16/share cash consideration implies ~$814M equity value on 257.7M shares outstanding; up to $100M additional CVR payments contingent on sales milestones
Risk Factors
- Shareholder vote failure: requires majority of all outstanding shares, not just votes cast — abstentions/failures to vote count as AGAINST
- Regulatory delay or antitrust conditions from HSR or German Federal Cartel Office
- CVR payments uncertain and could be zero if sales milestones not met
- Debt financing terms or conditions may delay close if tranche A funding conditions not satisfied
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001104659-26-071107 |
| Document: tm2615754-2_defm14a.htm | 0001104659-26-071107 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access